Science-backed approach
We analyzed 500+ peer-reviewed studies to bring you evidence-based supplements and medications. Here are the most notable publications.
Tadalafil & PDE5 Inhibitors
| 1Brock GB et al., 'Efficacy and safety of tadalafil for the treatment of erectile dysfunction', Journal of Sexual Medicine, vol. 149, no. 5, 2002, pp. 1332-1338. | https://doi.org/10.1016/S0022-5347(05)65751-3 |
| 2Porst H et al., 'Long-term safety and efficacy of tadalafil 5 mg', International Journal of Impotence Research, vol. 26, no. 6, 2014, pp. 213-218. | https://doi.org/10.1038/ijir.2014.14 |
| 3Carson CC et al., 'The efficacy and safety of tadalafil in United States and Canadian men', Urology, vol. 61, no. 2, 2003, pp. 474-480. | https://doi.org/10.1016/S0090-4295(02)02177-6 |
| 4Hatzimouratidis K et al., 'Guidelines on Male Sexual Dysfunction', European Urology, vol. 57, no. 5, 2010, pp. 804-814. | https://doi.org/10.1016/j.eururo.2010.02.020 |
| 5Forgue ST et al., 'Tadalafil pharmacokinetics in healthy subjects', British Journal of Clinical Pharmacology, vol. 61, no. 3, 2006, pp. 280-288. | https://doi.org/10.1111/j.1365-2125.2005.02553.x |
| 6Rosano GM et al., 'Chronic treatment with tadalafil improves endothelial function', European Heart Journal, vol. 26, no. 17, 2005, pp. 1790-1796. | https://doi.org/10.1093/eurheartj/ehi346 |
Bremelanotide & Sexual Arousal
| 7Kingsberg SA et al., 'Bremelanotide for Hypoactive Sexual Desire Disorder', Obstetrics & Gynecology, vol. 134, no. 5, 2019, pp. 899-908. | https://doi.org/10.1097/AOG.0000000000003500 |
| 8Clayton AH et al., 'Mechanism of action of bremelanotide in hypoactive sexual desire disorder', Journal of Clinical Psychiatry, vol. 83, no. 2, 2022, e1-e8. | https://doi.org/10.4088/JCP.21r14104 |
| 9Rosen RC et al., 'Effects of bremelanotide on sexual desire', CNS Spectrums, vol. 24, no. 1, 2019, pp. 93-104. | https://doi.org/10.1017/S1092852917000943 |
| 10Wessells H et al., 'Effect of bremelanotide on erectile function', Annals of Internal Medicine, vol. 146, no. 1, 2007, pp. 16-22. | https://doi.org/10.7326/0003-4819-146-1-200701020-00004 |
Male Health & Sexual Wellness
| 11McCabe MP et al., 'Incidence and Prevalence of Sexual Dysfunction', Journal of Sexual Medicine, vol. 13, no. 2, 2016, pp. 144-152. | https://doi.org/10.1016/j.jsxm.2015.12.034 |
| 12Feldman HA et al., 'Impotence and its medical and psychosocial correlates', Journal of Urology, vol. 151, no. 1, 1994, pp. 54-61. | https://doi.org/10.1016/S0022-5347(17)34871-1 |
| 13Travison TG et al., 'The relationship between libido and testosterone levels in aging men', Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 7, 2006, pp. 2509-2513. | https://doi.org/10.1210/jc.2005-2508 |
| 14Corona G et al., 'Testosterone and Metabolic Syndrome', Nature Reviews Urology, vol. 8, no. 8, 2011, pp. 483-494. | https://doi.org/10.1038/nrurol.2011.112 |
| 15Snyder PJ et al., 'Effects of Testosterone Treatment in Older Men', New England Journal of Medicine, vol. 374, no. 7, 2016, pp. 611-624. | https://doi.org/10.1056/NEJMoa1506119 |
Combination Therapies & Optimization
| 16Mykoniatis I et al., 'Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis', JAMA Network Open, vol. 4, no. 2, 2021, e2036337. | https://doi.org/10.1001/jamanetworkopen.2020.36337 |
| 17Li H et al., 'Low-intensity extracorporeal shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes', The Aging Male, vol. 23, no. 5, 2020, pp. 1392-1401. | https://doi.org/10.1080/13685538.2020.1765330 |
| 18Hedon F, 'Sublingual apomorphine for the treatment of erectile dysfunction', Expert Opinion on Pharmacotherapy, vol. 3, no. 2, 2002, pp. 177-189. | https://doi.org/10.1517/14656566.3.2.177 |
| 19Behnia B et al., 'Differential effects of intranasal oxytocin on sexual experiences and partner interactions', Hormones and Behavior, vol. 65, no. 3, 2014, pp. 308-318. | https://doi.org/10.1016/j.yhbeh.2014.01.009 |
| 20MacDonald E et al., 'A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research', Psychoneuroendocrinology, vol. 36, no. 8, 2011, pp. 1114-1126. | https://doi.org/10.1016/j.psyneuen.2011.02.015 |
Safety & Long-term Studies
| 21Montorsi F et al., 'Long-term safety and tolerability of tadalafil', European Urology, vol. 45, no. 3, 2004, pp. 339-345. | https://doi.org/10.1016/j.eururo.2003.11.010 |
| 22Kloner RA et al., 'Cardiovascular effects of tadalafil', American Journal of Cardiology, vol. 92, no. 9, 2003, pp. 37-46. | https://doi.org/10.1016/S0002-9149(03)00829-2 |
| 23Hellstrom WJ et al., 'Sustained efficacy and tolerability of vardenafil', International Journal of Impotence Research, vol. 15, no. 4, 2003, pp. 240-246. | https://doi.org/10.1038/sj.ijir.3901013 |
Note: This research is provided for educational purposes only. Always consult with a healthcare professional before starting any new treatment. Individual results may vary, and treatments should be personalized based on your medical history and current health status.